SCYNEXIS INC (SCYX)

↓ Download CSV

CIK 0001178253 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Fiscal year ends Dec 31

In fiscal 2025, SCYNEXIS INC reported revenue of $20.60M, up 449.9% from the prior year. The company ran a net loss, with a net margin of -41.8%. It held $59.03M in total assets against $9.65M in total liabilities.

Key ratios (FY2025)

-78.0%
Operating margin
-41.8%
Net margin
-17.4%
Return on equity
+449.9%
Revenue growth (YoY)
Metric (FY)2025202420232022202120202019201820172016
Revenue$20.60M$3.75M$140.14M$5.09M$13.16M$0$121.0K$257.0K$257.0K
Operating Income-$16.07M-$37.12M$72.67M-$85.76M-$60.84M-$51.15M-$48.92M-$29.98M-$26.32M-$27.82M
Net Income-$8.61M-$21.29M$67.04M-$62.81M-$32.87M-$55.19M-$53.71M-$12.47M-$25.06M-$29.99M
EPS (Diluted)$-0.17$-0.44$1.39$-1.47$-1.25$-1.58
Total Assets$59.03M$90.64M$128.41M$87.81M$119.84M$102.54M$57.15M$53.17M$45.85M$59.79M
Total Liabilities$9.65M$35.57M$55.45M$84.58M$78.58M$79.78M$44.26M$21.95M$24.44M$24.97M
Shareholders' Equity$49.38M$55.08M$72.96M$3.23M$41.26M$22.76M$12.89M$31.23M$21.41M$34.82M
Cash & Equivalents$21.26M$16.05M$34.05M$45.81M$104.48M$93.04M$41.92M$11.44M$11.47M$35.66M
Operating Cash Flow-$5.28M-$24.01M$60.16M-$79.88M-$54.56M-$49.35M-$38.12M-$28.32M-$24.56M-$29.35M
Capital Expenditures$0$4.0K$0$565.0K$2.0K$27.0K
Shares Outstanding43.54M37.97M37.21M32.68M28.71M19.66M9.74M47.97M28.97M24.61M